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Abstract 
 
 
Malignant fibrous histiocytoma is extremely rare primary malignant tumor of the heart. It is 
usually diagnosed when it is locally aggressive or has already metastasized. The prognosis 
is poor with the average survival time of one year. We report a case of recurrent left atrial 
malignant fibrous histiocytoma initially misdiagnosed as myxoma. The patient underwent 
repeated surgical resections followed by chemotherapy. Despite adjuvant chemotherapy, 18 
months after initial diagnosis definitive tumor relapse in left atrium was diagnosed. This is the 
48th case of primary cardiac fibrous malignant histiocytoma reported in literature.       
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Introduction 
Primary cardiac tumors are rare, with an autopsy incidence ranging from 0.001% to 0.03% 
(1). About three-quarters of these tumors are benign and nearly half of them are myxomas. 
Malignant fibrous histiocytoma (MFH) is the most common soft tissue sarcoma in adults, but 
is extremely rare as a primary tumor of the heart (2). MFH is a malignant tumor of fibriblasts 
and pleomorphic histiocytoid cells with large number of bizarre, multi-nucleated giant cells. 
Their stroma might be sometimes myxoid and moreover they might be occasionally 
misdiagnosed as a myxoma (3). Cardiac tumors present with one or more symptoms of the 
classic triad:  intracardiac obstruction, systemic embolisation and systemic symptoms like 
fever, arthralgia, weight loss and fatigue. The prognosis of patients having even 
nonmetastatic primary cardiac sarcomas is relatively poor with very few patients surviving for 
more than one year after diagnosis (4). Reasons for this dismal outcome are the diagnosis of 
this type of tumors in advanced stage of disease, impossibility to perform adequate radical 
tumor excision and the cardiotoxic side effects of radiotherapy and of some cytotoxic drugs 
(5). Early cardiac transplantation, if possible, might be a promising therapy for patients with 
nonmetastatic malignant cardiac sarcomas (6). We present the female patient with the 
malignant fibrous histiocytoma of the left atrium.   
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Case report 
A 58 year-old white woman was admitted to our hospital in September 2003 with history of 
congestive heart failure and bilateral pleural effusion three months ago. She underwent total 
thyreoidectomy with paraglandular resection and subsequent radioactive iodide 
administration in 2000 because of papillar carcinoma of a thyroid gland. On admission she 
was eupnoic in rest and afebrile, blood pressure was 140/90 mmHg, heart rate was regular, 
96 beats/min. Electrocardiogram revealed sinus rhythm with occasional extrasystolas. 
Pulmonary, cardiac and abdominal examination was unremarkable. There were no palpable 
lymph nodes. Transthoracic (TTE) and transesophageal echocardiography (TEE) revealed 
large, partially mobile tumorous mass 4x2 cm in the left atrium, which was partially 
obstructing blood flow through the mitral valve. According to its localization and appearance 
on echocardiography the tumor was suggestive for myxoma. No other tumor was found in 
the chest and abdomen. Open heart surgery under cardiopulmonary bypass was done and 
tumor was successfully resected; histopathology diagnosis was myxoma. Control TTE in 
December 2003 showed tumor recidive that occupied 2/3 of the left atrium. Re-operation was 
performed in February 2004 and maximal tumor reduction was done. Also the pathological 
specimen in paraphine block from first operation went for revision. Histopathology diagnosis 
was malignant fibrous histiocytoma (figures 1 and 2) for both specimens. No further therapy 
was applied and the patient was discharged. Control TEE done one month after re-operation 
showed local tumor recidive in the left atrium (figure 3) with complete tumor infiltration of left 
atrial free walls. CT scan showed no tumor propagation into the pulmonary veins or 
pericardium, and no systemic metastases were found. Because of extremely locally 
aggressive nature of the tumor the patient was scheduled for orthotopic cardiac 
transplantation. Subsequently, eight cycles of chemotherapy with doxorubicin and ifosfamide 
with mesna uroprotection were applied. Control TEE in September 2004 showed tumor 
remission after chemotherapy. Control echocardiography in April 2005 showed local tumor 
recurrence in left atrium measuring 1.2 x 1.2 cm. The next check-up in June 2005 indicated 
definitely tumor relapse because tumor size increased from 1.2 x 1.2 to 2.5 x 3.9 cm. 
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Moreover, the patient noticed the growing subcutaneous nodule on the plantar surface of her 
right foot which was resected in June 2005. The histopathology examination revealed 
malignant fibrous histiocytoma measuring 5 x 6 cm. Because of local tumor relapse and 
distal metastasis the patient has been removed from transplantation list. Four cycles of 
second line chemotherapy (cyclophosphamide, vincristine and dacarbazine) were applied 
from July to September September 2005. During the hospitalization for fourth chemotherapy 
cycle CT scan revealed a metastasis measuring 10 cm in diameter located predominantly in 
the vastus lateralis muscle. Gemcitabine and docetaxel were chosen for further 
chemotherapy and patient has received a first cycle in October 2005. Two and a half weeks 
after she was hospitalized because of acute massive pulmonary embolism, TTE showed 
tumor recidive which occupied more than one half of the left atrium (figure 4). Her condition 
improved after conservative therapy but this improvement was not sufficient for the 
continuation of chemotherapy. Unfortunatelly, only further therapeutic option left is very risky 
live saving surgical resection in the case of mitral flow obstruction.    
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Discussion 
Soft-tissue sarcomas are rare tumors accounting for approximately 1% of all cancers 
worldwide each year. There exists a variety of histological subtypes of sarcomas; the most 
common is malignant fibrous histiocytoma (MFH). The choice of treatment generally depends 
on the location, size and histological grade of the primary soft tissue sarcoma and patient's 
performance status. Surgical resection with pathologically proven clear margins is the 
treatment of choice for localized sarcomas. Postoperative radiation therapy plays a major 
role as an adjunct to surgery in improving local tumor control compared to surgery alone. 
Chemotherapy is also a treatment modality for the soft tissue sarcomas. Primary cardiac 
tumors including sarcomas are exceedingly rare. The majority of these are benign which are 
often successfully treated by surgical excision. In contrast, malignant cardiac tumors are 
associated with poor long-term survival despite surgery, radiotherapy and chemotherapy. 
However, surgical resection is often required for diagnosis or to relieve symptoms. Malignant 
fibrous histiocytoma is exceptionally rare primary cardiac tumor. Only 43 cases of surgical 
therapy for cardiac MFH have been documented since the initial report of Shah et al. in 1978 
(7). Among reported cases of MFH thirty patients (63%) were female and eighteen patients 
(37%) were male. Primary location of MFH is in the most of the cases left atrium, although it 
has been reported in the pericardium, right ventricle and/or pulmonary valve, right atrium, left 
ventricle and at the site of an atrial septal defect.  Very few data are available for the most 
appropriate management of cardiac sarcomas. At present, no uniform consensus exists 
regarding the best treatment strategies but therapy requires a multidisciplinary team 
approach. A radical surgical approach if possible represents the only effective therapeutic 
measure. But, in most of the cases complete resection is not possible either due to the local 
invasion or proximity to the vital structures. Radiotherapy due to its cardiotoxicity at radical 
doses can not be considered as an optimal therapy for malignant cardiac tumors. The doses 
which are effective are known to cause cardiomyopathy and chronic radiation pericarditis (8). 
Chemotherapy has also its limitations such as a relatively low response rates. Moreover, 
doxorubicin which is effective chemotherapeutic drug and therefore commonly used for the 
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soft tissue sarcomas is cardiotoxic what limits its usage and effectiveness in patients having 
cardiac sarcomas (9). For patients with unresectable or partially resectable heart sarcomas 
radiation and chemotherapy may be used, but without great expectation of long term tumor 
control. Limited evidence shows that selected patients with nonmetastasing MFH can benefit 
from orthotopic cardiac transplantation (6). Cardiac neoplasms have not been routinely 
considered for OHT because of concern for tumor recurrence and the possibility that 
immunosupression may stimulate further tumor growth. On the other hand, an increasing 
number of patients with treated malignancies such as Hodgkin’s disease and breast cancer 
have undergone successful OHT without an increase in primary tumor recurrence (10). In our 
patient maximal surgical reduction was performed. Knowing the malignant nature of the 
patient’s tumor, decision for cardiac transplantation and adjuvant chemotherapy while waiting 
for the organ was made. Doxorubicin and ifosfamide were selected for the first line 
chemotherapy regimen. Disease stabilization and even partial remission was obtained lasting 
for approximately 12 months. During second line chemotherapy the metastasis in the left 
thight was noticed indicating tumor insensitivity to these cytotoxic drugs. Combination of 
gemcitabine and of docetaxel was attempted (11, 12) but development of lung embolism and 
the deterioration of patient’s performance status prevented further application of 
chemotherapy. The radiotherapy was not applied because of already mentioned 
cardiotoxicity. In the case of soft tissue sarcoma distant spread is by the hematogenous 
route and lung metastases are the commonest metastatic site followed by bone and liver. 
Metastases in soft tissue are much rarer except in alveolar soft part sarcoma.  The presented 
patient during our follow-up has never developed metastases at the lung, bone or liver. 
Moreover, two distant metastases she developed were both in the skeletal muscles what is 
for the soft tissue sarcomas and probably for the heart sarcomas a rather peculiar metastatic 
sites. Strict follow-up of patients with MFH is mandatory because it has a high rate of 
recurrence and metastasing. Development of an optimal therapy for MFH will need improved 
understanding of the natural history and prognostic factors of this very rare disease. 
Adjunctive chemotherapy in conjunction with resection remains the first line therapy. The 
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potential gain of radiotherapy must be weighed against the risk of damage to myocardium 
and pericardium. The role of cardiac transplantation for primary cardiac MFH should be 
weighed on a case-by –case basis for patients who present with unresectable tumor and no 
extracardiac evidence of disease. 
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Figure legends 
 
Figure 1. Microscopic examination, MFH (HE stain, x200). Malignant fibrous histiocytoma 
revealing fascicles of plump spindled cells of varying size arranged in a swirling storiform 
pattern. Characteristic is the tendensy for the spindle cells to be disposed in a cartwheel 
storiform pattern.   
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Figure 2. Immunohistochemical examination, MFH (vimentin stain, x200). 
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Figure 3. TEE demonstrates early postoperative MFH recidive in the top of the left atrium. 
LA indicates left atrium; Ao, aorta; MFH, malignant fibrous histiocytoma 
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Figure 4. TTE (parasternal short axis) demonstrates MFH recidive that occupied more than a 
half the left atrium. LA indicates left atrium; RA, right atrium; RV, right ventricle; AO, aorta; 
MFH, malignant fibrous histiocytoma 
 
 
 
 
